Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Long-Term Investments (2025 - 2026)

Standard Biotools has reported Long-Term Investments over the past 6 years, most recently at $25.7 million for Q4 2025.

Quarterly Long-Term Investments changed N/A to $25.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $25.7 million for FY2025, N/A changed from the prior year.
Long-Term Investments was $25.7 million for Q4 2025 at Standard Biotools, up from $19.5 million in the prior quarter.
Over five years, Long-Term Investments peaked at $25.7 million in Q4 2025 and troughed at $19.5 million in Q3 2025.